Physician profile
Deepak Vadada
NPI 1003042672
$1,664.03
in general payments reported to CMS, 2019-2025
13 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $203 · 2021: $344 · 2022: $127 · 2023: $253 · 2024: $232 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.95 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $614.42 | 2019-2025 | |
| Janssen Biotech, INC. | $394.42 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.76 | 2019-2023 | Trulance, Xifaxan |
| Boston Scientific Corporation | $100.93 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.52 | 2019-2024 | Entyvio |
| Alnylam Pharmaceuticals INC. | $96.83 | 2020-2022 | |
| Celgene Corporation | $67.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.86 | 2019-2021 | |
| Covidien Lp | $40.32 | 2019 | |
| Braintree Laboratories, INC. | $32.57 | 2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $26.46 | 2019-2020 | |
| Steris Corporation | $14.12 | 2021 | |
| Allergan, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Vadada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.